Science & Technology
Restoring Tolerance with an Oral AMPK Agonist Nanomedicine Targeting Intestinal Dendritic Cells as a Preventative Therapy for Type 1 Diabetes
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41AI186895-01
Award Ceiling
$307K
Award Floor
$307K
Close Date
Jun 30, 2025
Total Funding
$307K
Expected Awards
1
Posted Date
Jul 22, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R41AI186895-01
Description
STTR Phase Phase I award: "Restoring Tolerance with an Oral AMPK Agonist Nanomedicine Targeting Intestinal Dendritic Cells as a Preventative Therapy for Type 1 Diabetes" awarded to Qrono, Inc. in Pittsburgh, Pennsylvania. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $306,500. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, HUBZone businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.